SPPI - Earnings call transcript Q4 2020 | Spectrum Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Spectrum Pharmaceuticals Fourth Quarter and Full Year 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. now today, hand Financial Kurt would to conference Officer. I speaker your Gustafson, Instructions] like the to over [Operator Spectrum Chief Please go ahead.

Kurt Gustafson

for year XXXX and everyone. results conference Spectrum Operator, afternoon financial fourth joining you Pharmaceuticals’ full you, for us and Thank quarter call. today good Thank to

release is fourth our available Our press website and earlier out at year full sent quarter on this results www.sppirx.com. financial was afternoon and

Dr. Turgeon, François call the from Pharmaceuticals President today and and Joe Riga, Officer. CEO; Chief Joining Chief me on Tom Lebel, will Spectrum Officer; Medical Operating be our

Before and this be the in the inherent we today’s These placed guarantees not afternoon. not major statements performance performance forward-looking periods call Spectrum. Such unknown or Joe and that, get forward-looking press started, may regarding to in make risks risks future and such the of or I materially in statements undue results on would are me hand future let of which With forward-looking like over necessarily to included reliance Turgeon, results performance expressed actual future implied emphasizes should uncertainties of involve statements to notice CEO any statements projections financial by reference release. uncertainties, statements. cause that them. and notice This will from differ the forward-looking known we and

Joe Turgeon

We in I momentum, XXXX, our the the the the team in number important made course and form across had and dedication, momentum for milestones allowed XXXX. a in to Spectrum recent of of it’s the on has achieve continuing XXXX, the us over overall activities Spectrum us focus the XXXX. joining in will excited finish call demonstrated here. to Good and strong for that you appreciate challenges biopharma that and industry. Thank of thank basis Kurt. achieved creativity key We your and despite that progress pandemic impact you, interest Throughout everybody, afternoon, maintain to which the is great today. XXXX Spectrum am be

met agreement a previously strategy poziotinib. FDA met primary the in we the of with FDA the pre-specified quarter, disease. with our that these proceed Phase poziotinib submission fourth X Fast the filing based it’s with X with positive exon patients Based indication. a the of to Spectrum granted and non-small review Adding the clinical for Cohort the with XX this designation to from exon reached evaluated insertion trial news, the Track our HERX the of data During ZENITHXX. an NDA to was lung positive discussions, this on patients. for results application endpoint for HERX for drug cancer on with for submission patients by mutations. cell treated XX that demonstrated This This devastating These recent welcome trial with poziotinib we this FDA the new is for news mutations

preparing NDA to currently submission FDA look a to later forward are We this year. and an the

is in inspection perform our of Regarding preapproval scheduled manufacturing ROLONTIS, facility FDA the May. to the

that year is result for facility COVID-XX it deferring world-class related restrictions travel to BLA Hanmi manufacturer of to South and inability may due was the inspection. their in FDA ready Hanmi last a the a experienced as they recall, on you Bioplant us pandemic. Korea to action with this Pharmaceuticals biopharmaceutical As informed the inspect an are

ROLONTIS Hanmi confidence approval received had Korea, matter our for readiness. further in recently a of raised their fact, manufacturing As in which

active development. remain our clinical program, addition immuno-oncology late-stage the business a licensing quarter, with for In we fourth new into In to entered we transaction advancing assay.

product say the our existing am confident meet aspiration them. objectives CMO, programs programs turn our portfolio. corporate clinical about addition to this to action. strategy our our this bringing our progress our and with example It like Dr. shows François of cancer that I’d synergistic I the more in of the our lead call Dr. a to with I build is and by our to in our execute treatments goals. the a and advance of development our Our pleased that to two ability François? the Spectrum Lebel, and that, assets dedication further François portfolio patients to with excited are over strategy of team CMO the later. With Lebel, oncology new to need great products and will on am to is Dr. have

Dr. François Lebel

I under quarter you in our Track achieved constraints. update. trial. will Good with based the today way two spite well later begin for It’s is Significant afternoon, and a on of Cohort data be clinical is scheduled of Fast positive our be has will Preparation under ZENITHXX poziotinib. NDA This COVID year. submission milestone for its of for good from X designation with important this the brief progress been everyone. to this in imposed

there less QD medical In data X with milligram approved Grade and dose March, confirmed This know, with evaluating initial for will data a improve to presented be weeks. HERX is or hypothesis. dose. data you be X from which pleased as dosing poziotinib be preliminary tolerability events. This early area AACR the we with an address need. HERX is from reduce and to activity, XX milligram, milligram, presented then, X and which as lung than exon of no or incidence improved XX X, has XX patients to non-small with led that Since BID potential interruption we milligram milligram in great to BID our of the we this Cohort data first two dosing. milligram EGFR and our antitumor efficacy patient additional X observed in mutation insertion lower adverse demonstrated to believe As XX on BID We further, matured this continue cancer treatment cell market very

ROLONTIS. shift to Now let me

supported is clinical clinical robust data by from randomized ROLONTIS large for BLA two Our trials.

Enrollment with that to the day the on our given evaluating that factors inspection for believe answered been inspection all which which dosing FDA of is create filing, the same day market are we BLA partner on and study to ready from have ROLONTIS day chemotherapy, has after difficulties satisfactorily We represents believe the ROLONTIS deferred scheduled dosing in can cell we May. today patients. Hanmi same the the exploratory white the for study the our that continues, Generally on that this have be FDA the growth for as the of the chemotherapy. step an Regarding logistical review our final in questions review and the we related action preapproval Joe process. mentioned, planned ROLONTIS

in in safety at Breast post-chemotherapy initial XX-minute XX X with evaluation our total hours, the patients are recently XX AACR. dosing of translational Following minutes, We patients. poster at expanding presented Meeting to safety examining results enrollment and Miami X we a a the have evaluation Cancer early of initial arm the hours March the nine at

or emerging in refractory have in sites a Now with This data in We recently again let’s or Phase escalating fusion dose with turn program suggesting We protein of immune-oncology our Therapeutics and non-Hodgkin ESMO for focus now directed CDXX safety is lymphoma, FIT. presented large is expressing interferon. IR a anti-CDXX conjugated a fusion at good consists profile. patients pipeline, B-cell Interferon starting treating rituximab B-cells to protein FIT in our opened antibody model X lymphoma. study an alpha to moiety relapse including enrolled. diffuse ROLONTIS for activity of

in suppressive known year immune master PCXXX As will asset have called preclinical number to cell. is new currently a when NK we as IL-XX filing for Spectrum and to This we a an a T is XXXX to Joe say the as big covering key a development mediators and get more tumor the of proprietary our in IND. a closer forward which With shown regulatory immuno-oncology milestones we solid regulator have tumors can readouts. an with our of licensing over the reprogram product Kurt progress cell tumor of look this, we review and and killing. further release system a controlled it formulation. a for sometimes microenvironment T cell will transaction year. mentioned, entered has multiple the of I enhance throughout to It updates financials. I IL-XX of in Therapyx to for been encapsulated turn you and on providing program reduce is are activity, data important

Kurt Gustafson

François. you, Thank

primarily market expense R&D while meet for the equipment secondary Much we $XX.X versus XXXX capacity demand fourth write-down SG&A to quarter value. was related expense one-time $XX.X our was million relates will to the assets of ago, a of which was million. Our X, was years our a charge year. down physical versus to three written ROLANTIS to about $XX.X million Bioplant in facility. fair manufacturing previous for expense question at installation recoverable, source of in actual R&D million the evaluated to there The increase $XX.X this ability $XX.X not forecast. their and equipment validation cost was Approximately Hanmi’s at peak when processes, be million

Since have manufacturing of significant a things a result, second time, we source commissioned invested this at a and that As capital facility. happened. couple

Bioplant First, Hanmi will and now their has constructed made of large commissioned. facility is and is greatly collaboration a X with brand capacity. was completion invested pharma with increase state-of-the-art facility in The ahead investment that new this in schedule of great in progress and partners fully

result, a manufacturer was secondary did the unlikely it a not for to meet Second, our solution deemed peak our us and as timelines be expectations demand. at for

discontinue impact the leading the to manufacturers, the So needs. solution We will of long-term to here we in what’s currently Hanmi’s a at of over to Bioplant XX the This and months manufacturing combination launch. Bioplant cost most secondary as discharge. is result, X two we and the has we term for effective U.S. economics your and efficient ready risks these have X site, of that decision made no And have work provide as the supply supplies. which on launch capabilities, evaluated believe our our supply

in value compared from loss XXXX. other time holdings ago. on the in loss basis, which fourth million, value Moving securities, of quarter $XX.X an $XXX primarily to non-GAAP the in versus in period $XX measure better in been On the the comparable a in Also of facility. relates did the in for a quarter. of year change cash versus issue loss in which down year continuing costs This million in plus Operating not to outflow XXXX, our last compensation year in have our was million We approximately the was the period. from ongoing expense, out a million we was the $XX.X where a the operations and clarity have net quarter. we which ATM approximately we $XX our our ended quarter on prior marketable CASI equity with a for CASI stock is million our to increase $XX.X when equity period for primarily Pharmaceuticals. timing time the the few are million million in consistent quarter previous is million impairment charge, million backs the securities, $X.X $XX.X the was of of This income the Out Again earn, with was the $XX.X quarter cash fourth one gain $XX inspection. million at FDA of the of first quarters. cash utilizing

now approval. call let to a launch are back a provide cash runway current position the forecasting We to poziotinib me hand now and Joe. sufficient that should our that, With ROLONTIS

Joe Turgeon

and François. you, Thank Kurt you, thank Dr.

strong remarks everyone’s forward and facility. that our We I Spectrum completion continues inspection from think steady of of make the progress the pipeline. to look on manufacturing ROLONTIS you to see our can

on in dedication Operator, you future that, please? Cohort open and we thank open We hard look our like I’d a clinical entire if sharing informed to trial. to Once their poziotinib for forward our will unprecedented keeping a in this these team the on their update for call of like progress. work the and again, ZENITHXX With could on and I’d ongoing to you of the you our results year progress NDA questions. times later for our up all call

Operator

Maury from your Raycroft [Operator you. Jefferies. question. Proceed Instructions] with Our with first comes Thank question

Joe Turgeon

Hey, Maury.

Maury Raycroft

thanks questions. my taking Hi, the everyone. Congrats progress Hi, and for everyone. on

steps First just your kind BLA has if wondering includes given the look data? you next one and which ROLONTIS of And the rest is specific any on like question. you just feedback of a inspection can FDA clinical what filing on the provide timing naive there? more But into after clarity could

Joe Turgeon

you want on do François, to that? comment

Dr. François Lebel

Sure.

is say the step that the to just only review got let’s knowledge opposed -- our with a start me let So pausing response when the we inspection. that to left complete the is, that CRL and they usually as FDA are deferral their indicates

We is all and the we all have with questions have the had a lot that of understanding FDA their satisfactorily. matters answered discussion on our other

step. is the believe the last inspection So fundamentally we

to the roughly more activities I inspection issues, to and an tell pass month, little As a there’s ballpark are about what colleagues think no the assuming you launch than one maybe figure to it a on following timing I that’s that will you of if probably, is asking. I guess my

Maury Raycroft

will That more be into that as to go great activities you well. Yeah. would want Sure. helpful be if launch

Joe Turgeon

Yeah. Tom you launch readiness? why your don’t on comments

Tom Riga

Hey, Maury. It’s Tom.

We are this launch. we are can’t thrilled wait and we to approval for ready

upon be will force approval. We out in

We have the leadership team in place.

thereafter hiring to gated vast generation demand will begin inspection the been May. have majority are of our forward this and identified We looking which and reps, sales a soon in has we approval we

Maury Raycroft

Got it.

you X you and additional patients mutational be can wondering at just Cohort Okay. relative to to AACR are maybe how TAT That’s update? going much many patients are break helpful. going by And AACR, to and on out ESMO say status follow-up the how follow-up one if

Tom Riga

Right.

with of start communication. me the nature the Let

we be So to EGFR going speaking HERX dosing. are be patients, focusing the we on and and will both on

X So of anti-tumor XX-milligram as BID. XX-milligram the safety activity, words, the XX-milligram, as and activity X as and the profile in we to provide result well going to other are well as and

So will steps the of on we the focus actually reporting that’s communication total. for be patient next XXX and the initial

Maury Raycroft

Great.

of on know patients? are I And the you Okay. time the you are for saying looking amount follow

Tom Riga

be -- vary all Yeah. reporting we Well, fresh will we because very the results. up will follow these -- simply will report

communicate be AACR. to But say will that AACR. confident we going we just can this at and to obviously, we data some conclusion report at detail will are there’s preliminary data I come more time, So, have that at we and

Maury Raycroft

very taking for my you Thank Okay. questions. much

Tom Riga

Sure.

Joe Turgeon

Thank you, Maury.

Operator

you. Thank

next with Cantor Our comes question from Alethia Fitzgerald. Young

with question. proceed may your You

Emilia Falcetti

if you our up is kind FDA progress. again? This is there questions assumed risk or already the any do pushed on of for has I their that like for be the doing that that’s May or congrats on definite feel timeline back for is starting timeframe wondering May international the Thanks inspections I pretty taking timeframe? that begun Emilia guess, Hi. could a is Alethia. and was if

Joe Turgeon

answer. Yeah. will Thanks, Emilia. I

FDA’s have I gone have the personnel position to only all, in But of First COVID. can Hanmi with met I answer our going can COVID with done. to everything that international we be on already through the can -- is general you all May. and is for speak and they The ours. inspections. they have already I they what all up And procedures -- way are set come in tell

being So everything is set up.

So we the to forward done something in are having looking unless we crazy feel May. happens, that inspection

Emilia Falcetti

Great. Okay. you. Thank

Joe Turgeon

Thank you.

Operator

you. Thank

White Our comes question Wainwright. Ed H.C. from with next

You may proceed with question. your

Ed White

taking questions. for my Thanks guys. Hi,

Joe Turgeon

Hi, Ed.

Ed White

Joe. Hey,

on to perhaps So alone? mutations? EGFR about Cohort potential BID as expand how far market should pozi thinking dosing, there as we XX a readdress focus and the goes this be X or is exon With new EGFR develop study in, the a to

Dr. François Lebel

Yeah. Ed, François.

So very good question.

line, other X we primary we X primary across pretty We met X the consistently Cohort Cohorts, clinical are nonetheless. endpoint know, second significant have obviously, the on As and shown HERX not but Cohort activity showed Cohort you although met there endpoint.

will we AACR. So Cohort of actually which but X re-examining am one EGFR at and/or EGFR that The and enrolling present yes, from will were patients we HERX sorry was data and not majority or patients. both, are either I come

comments and So their impact. be on data off reporting as I the press. said strategy we Obviously, general fresh the making is will and various the dosing

informative. think, preliminary, it but going nonetheless, be So very to will be I it’s

Ed White

were lot SG&A Kurt, numbers. thinking Okay. in perhaps we the as And about for one-time forward mentioned then expenses Thanks, a you and R&D factors of quarter François. fourth going there be should question how a

to wondering SG&A throughout Thank just is force So I the forward just Tom I the ROLONTIS, hire of you. approval, thinking then sure XXXX? want make for be you to that we am get it And correctly? should sales about heard I R&D how and that once so going costs going seems bulk

Kurt Gustafson

No. Yeah.

we that pretty be, been would guess, SG&A on have just I number. a costs, you around guidance the consistent at I if look Ed, historically So, take million give $XX you would

Now per hire additional will increase. it’s quarter, to dramatic that not up be that a so number is as But not marketing costs be go going as But slightly this So will right? number folks. big sales we sales a there well. team

depending it So move that whether will actual inventory. bit go can a up little we as of launch to ROLONTIS. into can number not the around period be, are we for kind regards that or R&D, on With bounce buying

material as those possession so as sold of down. numbers out preapproval bump take a and recall, you it would we of inventory that of goods can purchased as be approval, cost eventually. up sell is and R&D When an that we cost zero costs we it, come Post it that’s classified kind the booked when As when will inventory.

R&D So see go for actually costs that you might perspective down.

think you kind give quarter over a go for So good take you average it the you around time general a of bit. can back if quarter-to-quarter can could of but bounce period just a in look it previous longer and I a little signal

Ed White

Okay. you, question on Kurt Oh, the... one Thank Kurt. last

Kurt Gustafson

Yeah.

Ed White

the this million you of were number million thus that issued $XX shares $XX What On was associated raise? the ATM, had with far a that raise year.

Kurt Gustafson

around Ed X.X tomorrow. the to report I going million go those let me and we have to my look XX-K is in am shares. back recollection right numbers will -- But

Ed White

you. Thank Great. Okay.

Joe Turgeon

Thank you, Ed.

Operator

Thank you.

Riley proceed comes question. with next question with Please Our B. Securities. from Mayank your Mamtani

Sahil Kazmi

Sahil quarter. is on on Kazmi Mayank. for Congrats the This in team. progress afternoon Good Hi. all the

some the efficacy and that the NDA to maybe side agency the couple just info same relating be from from the and AACR and Any data XX with this the sort ongoing afterwards? expected us, might on then a questions brief from that it brief may of tolerability safety to Just to the of X? dosing data Cohort submission as in question a on both benefit first relevant Is dosing Cohorts. day trial relates include

Joe Turgeon

Sure.

So, have done is discussion yes, had to endpoint the pre-specified And little actually look, day Cohort exceeded the met NDA we we know, per bit. X as was Cohort X. the the with FDA relates so far and with a XX-milligram you and

the that’s submission. the to focus going be So of

dose essentially you including to the what justification. the do about efficacy, FDA submission et safety, section drug about information provide cetera, ask when a Now called you complete and a

be providing and of adverse obviously to have BID pretty actually event. know, before on recently are and So going impact BID that significant in findings better reduction you ESMO dosing we as additional presented we about with dosing, them but our some signal also positive anti-tumor activity, information had at a just

So information Cohort will but X. the we see and is submission of will good we core discussion, definitely the have the

Sahil Kazmi

you Great. That’s you And of forward? trial expanded enrollment with you. very think can how helpful. dosing in about as about think the about the same-day then, the you context ROLONTIS, Thank talk path the

Joe Turgeon

Sure.

So XX-hour done drug fundamentally rapid we trial the from as And we patients, seen when not -- Meaning that we dramatically different neutropenia well. recovery sure the large want confirm which had want XX there. we to XX we make from later. are the we more gave the the to we was saw same the seeing expansion pivotal to that attributes is profile in safety minutes,

things if would path a all discussion to we with in the probably are those forward. FDA So engage seen

then but the now the step do in until plans FDA. XX to We detail go talking don’t some expanding we want next to and I to have developed of

Sahil Kazmi

look Got very right. you our the progress. at much data much for on very Congrats Thank AACR. questions it. taking to All the forward and

Joe Turgeon

you. Thank

Kurt Gustafson

your on looked can Ed you up Thank I hold you. Operator one if number. second.

shares line million we were still are the that you quarter. in If was issued X.X on the it

continue, Operator. can You

Operator

Thank you.

Benjamin proceed next question with Please your Securities. with question. JMP Reni comes Our from

Reni Benjamin

quarter, confirm a Thanks and presumably the forward make comments congrats the we an have see made after because lastly Hey. the to bit kind wait about thinking Good we before kind guys. or And right are about fourth little made were the onboard quarter thinking it’s you sure I guess about that seeing to of it inspection’s that should have how am really can an on could approval, heard as occur? could that the talk hired we coming taking as questions just be a you people get this have right. I up. to afternoon, rollout thinking the all is it for do just in I you to for after XX well. know revenues I they is inspection Great the a of on be we launch want revenues? make and launch, based to and that about expect just done third going want kind how staggered be can FDA month sales decision that start I And to moving we should long quarter, decision. the of be

Joe Turgeon

going part Yeah. the is start to and month itself on Tom said are launch Generically clarity. what timing that’s am we a To that comment am going about first saying. I time Reni, takes cetera. this it it, I usually on and your and et we Joe. the don’t so more your we to let equation the or of answer exact of revenues, know

that’s indicated get the we to because last But when step for CRL the we don’t been we have a So the us procedure got sure didn’t back feel less. and here, will will deferral. to that I we in I want get what we back agency know stress the when

thing this after do piece. the other we So to assume is and the we There is last no last hope that. is this

that’s hope drugs. month. speaking approvals. So generically on that other about That’s we helps I other why that a from said just And drug

you why the -- through walk of on the launch. Tom, timing happening what’s the don’t in Now,

Tom Riga

of the XX today. FTEs by Sure. have reminder, Reni, XX I think, of we just way onboard approximately

will inspection onboard. attributed So will the folks those a and successful preapproval bring we upon be hiring

generation all the pretty plus So engage and in customers begin contract team, approval beginning with leadership to you if rollouts you are short order thinking demand about post-approval.

things customary PIs to You like training have number would printed. final certifications, affixed license being the and syringes, then being

about channel think we for biologics weeks eight how demand is be to kind you post-approval of with real that. weeks generation line are four about and product filled thinking in think I to

Reni Benjamin

not remind regarding Got biosimilar, what’s of where you you have it. are remind the that? because reimbursement, can discussions me can of are some us just a you it’s And you differentiated, been you having kind

Tom Riga

Yeah.

we CMS. final approval active very trigger been So have and to label the and submission will the

But a J-Code, and product launch reporting and is for ultimately would ROLONTIS and with rebates a initial in there in and neighborhood they then upon of unilateral would JXX the level not be. miscellaneous be timing reimbursement. to else’s be customer of to would timing, anybody be CMS you is of you approval quarter those would stability the product, CMS about figure would our the Code at or shorten activity would have the of contingent actual I reimbursement would how So the day depending actual CMS the predictability equates customers launch as timing think thinking own then miscellaneous that J-Codes other used independent control that permanent of on on And the to should we BLA the what the and with are dating for windows end than issue be what a of J-Code, terms ours. we miscellaneous extend would at discounts they windows, depending a then

physicians GCSF a and both time we and think in competitive us real kiosk significant we look we unique there it when advantage a a opportunity offer of be fair white an gives market alternative So think it’s amount at when cell to a a within choice. is this, at very

Reni Benjamin

to we question to Got get I results, or same-day we am me how just a I a you months seems we guess think expansion sort but could to some bit of a be six say little a a it. be if larger on able then that patients. you And so, do how patients? within to those think with with is just let’s to study, you of label XX maybe do my the -- previous maybe going for Perfect. if straight back one that going have one of timing off. the dosing actually say it’s you patients. come might the these like or And bridging I -- to study -- question, the with number those expect these able guess modify according to When up go correct It up FDA just the -- might quickly

Dr. François Lebel

Yeah.

take So I it’s François. will that one.

be that under clear that the the BLA want is just I we in the initial the where last filing so. inspection review are that’s we to least So talking step believe at

we same have day dosing about anything near-term. don’t in potential that approval So the in

from the longer. -- the especially originator the different or in novel it’s biosimilar difference as in because as marrow data, earlier saw really it is Now has we the we confirms it it sense get -- is meaningful stays that of that it the what through attribute if expansion, it product truly adds some the soon it kinetic -- and our go different there and pharmacodynamics that of

it behavior here all different make the So, others. and little its these attributes from in a

have expansion really And strength next And with is step more be and the study. now the to but to so tell the those way the elements to get those to next what the the to are see going going could the signal you discussed we we wait I in unfortunately We FDA that’s would of results. on as I that… to depending design our affect wish think by have

Reni Benjamin

Okay.

Dr. François Lebel

patients rapidly. those be don’t …we difficult able expect long recruitment. quite to a or We should recruit protracted

Reni Benjamin

Got it.

there happens looks Cohort the point? understand based on for various François. of dosing Thanks Kind I question that we what insertions, are change for have XX number then for you, themselves a we expand HERX out you for you really to get mgs, the guess these and to study? patients want expanded am we approved next utilize final steps, schedules. just do a kind what X, exon probably No. patients, like Do feel leave X label XX let’s on schedule okay, what trying exon formal manuscript HERX say, -- do one published as modify you gets pozi good dosing really once out proper as it literature we can look, -- there the of or of well that. conducting it’s patients. The guess a at of Okay. it kind just I get I that clarity and BID that decide, physicians EGFR, by as maybe and the that to

Dr. François Lebel

Yeah.

I or ahead XX to so. don’t myself days want So in look here of get

and You presentation. to are then going abstract the see the

HERX, obviously, obviously the for do need it would if The So, timing that. we That’s other good assume that EGFR looks good than thing signal normal to continues is to one with with we be of do. would be a that the be that against would and wait obviously would But that further discussing Cohort natural the FDA right? the critical. you good, thing expansion

to We to it when because change PDUFA can FDA, careful data present your date. the you be have new

appears a development. we comparison got share to that. here. have certainly got at designation. drug we cautiously. be to and AACR. provide Track proceed some of have very will real in and the have we a And other So some very reason want pozi good good we to data same you think that But we we careful for to the at There’s time medical in And need Fast There’s thing the

Reni Benjamin

much very questions. Thanks the for great. Sounds taking

Joe Turgeon

Reni. Thanks,

Operator

time. Thank Joe call any the am at Turgeon now any like turn over further remarks. not showing this you. further to for questions And I would I to back

Joe Turgeon

along other the you like call will it all to appreciate afternoon like say interest participation really have to everybody and Josh. speaking be we for great call And I’d and be we will today. and conclude everybody’s financial here. the the I’d and I the meetings on a of in way you, Thank thank

goes as look at you interest. for the your year data AACR Thank and out. presenting very much we So to future forward

Operator

participating. conference gentlemen, you. Thank Ladies concludes today’s this for Thank you call. and

now You may disconnect.

Spectrum Pharmaceuticals (SPPI) 31 Mar 212020 Q4 Earnings call transcript